Cargando…

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%

BACKGROUND: The purpose of this study was to characterize intraocular pressure (IOP) reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily in the evening. METHODS: The results of seven published, randomized clinical trials including at least one arm in which travop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubiner, Harvey B, Noecker, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334204/ https://www.ncbi.nlm.nih.gov/pubmed/22536047 http://dx.doi.org/10.2147/OPTH.S30690

Ejemplares similares

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%
por: Gross, Ronald L, et al.
Publicado: (2007)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado, Ahmed Salah, et al.
Publicado: (2012)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis, Vassilios, et al.
Publicado: (2018)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell, Joanna H, et al.
Publicado: (2014)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
por: Naito, Tomoko, et al.
Publicado: (2016)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa, Vital Paulino, et al.
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs
por: Inoue, Kenji, et al.
Publicado: (2012)

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy
por: Lerner, Simon Fabian, et al.
Publicado: (2017)

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
por: Quaranta, Luciano, et al.
Publicado: (2015)

Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
por: Perera, Shamira A, et al.
Publicado: (2016)

Dielectric and Electric Properties of Ba(0.996)La(0.004)Ti(0.999)O(3) Ceramics Doped with Europium and Hafnium Ions
por: Adamczyk-Habrajska, Małgorzata, et al.
Publicado: (2022)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: Henry, J Charles, et al.
Publicado: (2008)

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
por: Nomura, Yuya, et al.
Publicado: (2010)

Efficacy of MAP0004 in treating severe migraine
por: Kori, S, et al.
Publicado: (2013)

Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
por: Kumar, Suresh, et al.
Publicado: (2019)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: A randomized clinical trial
por: Kiddee, Weerawat, et al.
Publicado: (2017)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Travoprost Induced Granulomatous Anterior Uveitis
por: Chiam, Patrick
Publicado: (2011)

Efficacy of travoprost for the treatment of patients with glaucoma
por: Zhang, Xiu-Li, et al.
Publicado: (2019)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Cosmology, Gravity, and the WMAP ratio 0.73:0.23:0.04
por: Smith, F D T
Publicado: (2004)

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects
por: Mizoue, Shiro, et al.
Publicado: (2014)

Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma
por: Igarashi, Ryoko, et al.
Publicado: (2014)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

The management of glaucoma and intraocular hypertension: current approaches and recent advances
por: Noecker, Robert J
Publicado: (2006)

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Comptia Project+ study guide: exam PK0-004
por: Heldman, Kim
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u8emjpt1jfq65aeo25aq81dg12